Advertisement
Advertisement
BIO.B
Bio-Rad Laboratories, Inc. Class B
365.08
USDSponsored
0.00
0.00%
Aug 25, 15:58 UTC -4
Closed
Pre-Market
400.20
+35.12
+9.62%
BIO.B Earnings Reports
Positive Surprise Ratio
BIO.B beat 30 of 43 last estimates.
70%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$657.15M
/$2.26
Implied change from Q2 26 (Revenue/ EPS)
+0.95%
/-13.74%
Implied change from Q3 25 (Revenue/ EPS)
+0.64%
/+0.44%
Bio-Rad Laboratories, Inc. Class B earnings per share and revenue
On Aug 04, 2026, BIO.B reported earnings of 2.62 USD per share (EPS) for Q2 26, beating the estimate of 1.76 USD, resulting in a 48.43% surprise. Revenue reached 651.00 million, compared to an expected 630.23 million, with a 3.30% difference.
Looking ahead to Q3 26, 6 analysts forecast an EPS of 2.26 USD, with revenue projected to reach 657.15 million USD, implying an decrease of -13.74% EPS, and increase of 0.95% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Bio-Rad Laboratories, Inc. Class B's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bio-Rad Laboratories, Inc. Class B reported EPS of $2.62, beating estimates by 48.43%, and revenue of $651.00M, 3.3% above expectations.
How did the market react to Bio-Rad Laboratories, Inc. Class B's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Bio-Rad Laboratories, Inc. Class B expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Bio-Rad Laboratories, Inc. Class B's next earnings report?
Based on 6
analysts, Bio-Rad Laboratories, Inc. Class B is expected to report EPS of $2.26 and revenue of $657.15M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement